Skip to main content

Advertisement

Table 3 Subgroup survival analysis for patients with early- and late-stage breast cancer (%)

From: The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study

Characteristic Early-stage Late-stage
Total (cases) 5-year OS rate (%) P valueb 5-year CSS rate (%) P valueb Total (cases) 5-year OS rate (%) P valueb 5-year CSS rate (%) P valueb
Histological grade < 0.01   < 0.01    < 0.01   < 0.01
 Well differentiated 283 96.8   97.5   25 92.0   92.0  
 Moderately differentiated 1971 94.3   95.0   359 74.7   76.0  
 Poorly differentiated 685 90.3   91.3   155 60.1   61.4  
 Unknowna 575 92.7   94.0   134 63.2   63.2  
Histological type 0.66   0.41    0.89   0.73
 Ductal 3089 93.4   94.1   597 70.1   71.2  
 Lobular 103 92.1   95.0   26 63.9   63.9  
 Others 322 94.1   95.6   50 67.9   67.9  
Molecular subtype < 0.01   < 0.01    < 0.01   < 0.01
 Luminal A 1897 95.2   95.8   299 77.1   77.8  
 Luminal B 390 94.0   94.2   90 69.1   71.3  
 HER2 256 90.9   92.4   78 58.3   61.7  
 Triple-negative 371 88.6   89.4   91 60.4   60.4  
 Unknowna 600 91.7   93.3   115 65.8   65.8  
  1. Of the total 4640 patients, 453 with unknown stage at diagnosis were not included in the analysis
  2. OS overall survival, CSS cancer-specific survival
  3. aUnknown data were not included in the statistical tests
  4. b P values were calculated using log-rank test